A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis

NCT ID: NCT00963313

Last Updated: 2014-09-23

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 29 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2014-06-30

Brief Summary

Based on published data and according to the approved product label for ankylosing spondylitis and psoriatic arthritis, it can be expected that adalimumab 40 mg every 14 days should be effective in psoriatic arthritic patients with axial involvement.

Detailed Description

A recent review from GRAPPA group evaluates therapies for PsA including peripheral and axPsA. Analysing particularly the results with present biologic therapies it has been proven that outcome data at 24 weeks show excellent results in the treatment of peripheral forms of PsA with either of the three biologics disposable in the market, that is to say infliximab, etanercept and adalimumab.

However when it comes to analyse data on PsA patients with axPsA there are not results at all. The design of clinical trials did not evaluate axial outcomes and therefore there is not a possibility of knowing whether these therapies are useful in axPsA.

This is an open label multicenter study designed to evaluate the effectivity of adalimumab 40 mg every 2 weeks during 24 weeks in patients with active axial PsA despite receiving Methotrexate, Sulfasalazine, Leflunomide or Cyclosporine, plus NSAIDs and no more than 10 mg of corticosteroids.

Conditions

Psoriatic Arthritis

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Adalimumab, injection

Adalimumab, one injection every fourteen days during 24 weeks.

Adalimumab (HUMIRA®)

Intervention Type: DRUG

Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.

Interventions

Adalimumab (HUMIRA®)

Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.

Intervention Type: DRUG

Other Intervention Names

HUMIRA®

Eligibility Criteria

Inclusion Criteria

• Males and females aged between 18 and 70 years.
• A negative pregnancy test for women of childbearing potential during the screening period.
• Subject must be evaluated for active or latent TB (tuberculosis) infection by using a PPD skin test (Mantoux test), Booster test, chest x-ray and detailed review of subjetc´s medical history.
• Subjects to whom the doctor has decided to prescribe adalimumab, because of fulfilling the requirements for this treatment.
• Diagnosed with PsA according to CASPAR criteria.
• Axial disease according to radiological criteria (at least unilateral sacroilitis grade II) and spinal inflammatory symptoms.
• Disease duration of no less than 24 weeks
• Patients with peripheral involvement (mixed forms of APs) must have been taking MTX for at least 12 weeks before screening and at stable doses of 10 to 25 mg/week for 8 weeks before screening, or salazopyrine up to 3 mg/daily, or cyclosporin 2mg/kg or leflunomide 20 mg daily in the same conditions as MTX.
• Patient's doses of NSAIDs and oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) should have been kept stable for 4 weeks before screening.

Exclusion Criteria

• Contraindications for treatment with anti-TNF.
• Prior treatment with other TNF inhibitors or other investigational drugs during the last 30 days (etanercept 4 weeks, infliximab 8 weeks).
• Uncontrolled diabetes.
• Uncontrolled high blood pressure.
• Unstable ischemic heart disease.
• Congestive heart failure.
• Severe pulmonary disease.
• Chronic leg ulcer.
• History of cancer or malignant lymphoproliferative disease.
• Positive serology for Hepatitis B indicating active infection or positive serology for Hepatitis C.
• History of positive HIV status.
• Persistent, recurrent or severe infections requiring hospitalization or treatment with oral antibiotics within 14 days prior to enrollment.
• Previous diagnosis or signs highly indicative of central nervous system demyelinating diseases.
• Active tuberculosis, histoplasmosis or listeriosis.
• History or presence of confirmed blood dyscrasia.
• Female subjects who are pregnant or breast-feeding.
• History of clinically significant drug or alcohol abuse in the last year.
• Treatment with MTX, salazopyrine, ciclosporin or leflunomide initiated within the last 4 weeks before the screening. Treatment with corticosteroids (>10mg/day or equivalent or modified dose within the previous 4 weeks before screening). And patients where an intraarticular corticoid infiltration has been practised within the last 4 weeks before the screening will be excluded from the study.
• Treatment with more than one NSAID within the last 4 weeks before the screening.
• Patients treated with any DMARD different from MTX, cyclosporine, leflunomide and sulfasalazine.
• Dosage of concomitant MTX, cyclosporine, leflunomide and sulfasalazine must be stable during the study, otherwise it should be properly justified and recorded in the case report form.
• Patients treated with any analgesic different from acetominophen, NSAIDs, oxycodone, codeine, propoxyphene, tramadol, hydrocodone or combinations of these products or equivalents. The use of potent opioids is not permitted.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dr. FRANCISCO J. BLANCO-GARCIA

OTHER

Sponsor Role: lead

Responsible Party

Dr. FRANCISCO J. BLANCO-GARCIA

MD, PhD

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Francisco J. Blanco-Garcia, MD, PhD

Role: STUDY_CHAIR

Complejo Hospitalario Universitario A Coruna

Locations

Complejo Hospitalario Universitario A Coruna

A Coruña, A Coruna, Spain

Hospital Arquitecto Marcide-Novoa Santos

Ferrol, A Coruna, Spain

Hospital de Elche

Elche, Alicante, Spain

Hospital Comarcal Villajoyosa

Villajoyosa, Alicante, Spain

Hospital del Mar

Barcelona, Barcelona, Spain

Hospital Vall d´Hebron

Barcelona, Barcelona, Spain

Hospital Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Parc Tauli

Sabadell, Barcelona, Spain

Hospital Basurto

Bilbao, Bilbao, Spain

Hospital San Pedro de Alcantara

Cáceres, Caceres, Spain

Hospital General de Jerez

Jerez de la Frontera, Cadiz, Spain

Hospital Universitario Reina Sofia

Córdoba, Cordoba, Spain

Hospital Doctor Negrin

Las Palmas, Gran Canaria, Spain

Hospital Insular de Las Palmas

Las Palmas, Gran Canaria, Spain

Hospital Orense

Ourense, Orense, Spain

Hospital Pontevedra

Pontevedra, Pontevedra, Spain

Hospital Meixoeiro

Vigo, Pontevedra, Spain

Hospital Central de Asturias

Oviedo, Principality of Asturias, Spain

Hospital Monte Naranco

Oviedo, Principality of Asturias, Spain

Hospital de Salamanca

Salamanca, Salamanca, Spain

Hospital Donostia

Donostia / San Sebastian, San Sebastian, Spain

Hospital Virgen de la Macarena

Seville, Sevilla, Spain

Countries

Spain

Other Identifiers

SUE-ADA-2009-01

Identifier Type: -

Identifier Source: org_study_id